Company Overview and News

 
Rounds Report: Crispr Rallied While FDA Developments Could Benefit Gene-Based Innovators

2018-04-20 seekingalpha
Shares of Crispr continued to trade further North. The management is gearing up the next growth phase by streamlining its team.
Upvote Downvote

17
PLX / Protalix BioTherapeutics, Inc. FORM 8-K (Current Report)

2018-04-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
Rounds Report: Nephros And Protalix Bulls Charged Ahead While Crispr Insiders Built Shares

2018-04-15 seekingalpha
After a robust rally for the week, investors closed out the Friday’s session with skittish sentiments. Notable stocks under our coverage defied the overall market downtrend include Nephros, Crispr, and.
Upvote Downvote

1
Portfolio Review: Continued Market Outperformance In Q1 2018

2018-04-15 seekingalpha
Integrated BioSci Investing outperformed all benchmarks since inception as we’ve compounded at the 30% rate. For the same period, the XBI, DOW, and IBB procured 27%, 15%, and 9%, respectively.
Upvote Downvote

1
BioSci Research On Myovant Sciences (Part I): Is This A Big Winner In The Making?

2018-04-09 seekingalpha
Myovant is innovating a stellar molecule (Relugolix) for the treatment of pain and heavy bleeding associated with endometriosis and uterine fibroids, respectively.
Upvote Downvote

 
PLX / Protalix BioTherapeutics, Inc. null

2018-04-03 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0P(# @;V)J#3P\+TQI;F5A
Upvote Downvote

6
PLX / Protalix BioTherapeutics, Inc. DEFA14A

2018-04-02 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

4
PLX / Protalix BioTherapeutics, Inc. DEFA14A

2018-03-23 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

1
PLX / Protalix BioTherapeutics, Inc. FORM 8-K (Current Report)

2018-03-21 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

1
PLX / Protalix BioTherapeutics, Inc. FORM 10-K (Annual Report)

2018-03-06 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

1
PLX / Protalix BioTherapeutics, Inc. DEFINITIVE PROXY STATEMENT

2018-03-06 sec.gov
tv486986-def14a - none - 2.690533s
Upvote Downvote

5
Protalix BioTherapeutics' (PLX) CEO Moshe Manor on Q4 2017 Results - Earnings Call Transcript

2018-03-06 seekingalpha
Good day, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Year End 2017 Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a Q&A session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to Mr. Yossi Maimon, CFO. Sir, you may begin.
Upvote Downvote

PLX : Protalix BioTherapeutics Stock Analysis and Research Report

2017-10-02 - Asif

Protalix BioTherapeutics is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx® protein expression system, or ProCellEx. The company developed its first commercial drug product, ElelysoTM, using its ProCellEx system and The company is now focused on utilizing the system to develop a pipeline of proprietary, clinically superior versions of recombinant therapeutic proteins that primarily target large, established pharmaceutical markets and that in most cases rely upon known biological mechanisms of action. With its experience to date, The company believe ProCellEx will enable it to develop additional proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. The company is now also applying the unique properties of its ProCellEx system for the oral delivery of therapeutic proteins. On May 1, 2012, the F...

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 74365A101